CoChat

Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis

KUROKI, T, NAGAO, N, NAKAHARA, T · 2008 · Progress in brain research

The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.

Abstract

Newer atypical antipsychotic drugs such as risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole that have been modelled on the prototype agent clozapine and developed since the 1990 s are now referred to as second-generation antipsychotic drugs (SGAs). It has been proposed that the interaction between serotonin (5-HT) and dopamine systems may play a critical role in the mechanism of action of atypical antipsychotic drugs because a relatively potent blockade of 5-HT(2A) receptors coupled with the weaker antagonism of the dopamine D(2) receptors is found to be the only pharmacological feature which most atypical antipsychotic drugs have in common. This so-called 'serotonin-dopamine hypothesis' has become a useful model for developing new SGAs to achieve superior antipsychotic efficacy with a lower incidence of extrapyramidal side effects compared to those with first-generation antipsychotic drugs (FGAs) such as haloperidol and chlorpromazine, although it has not been validated yet. In contrast, it has been proposed as the alternative 'fast-off' theory according to which atypical profile of SGAs can be determined by the loose D(2)-binding kinetics alone, while the blockade of the 5-HT(2A) receptor may be neither necessary nor sufficient. This chapter reviews the current issues on the serotonin-dopamine hypothesis together with further advances in research on the role of 5-HT receptor subtypes in the mechanism of action for SGAs. In particular, SGA-induced dopamine release in the prefrontal cortex, possibly through the functional activation of 5-HT(1A) receptors by 5-HT(2A) and D(2) receptor-mediated interaction, has been thought to be the basis for the neurocognitive effects of these drugs on schizophrenia. Thus, the novel antipsychotic aripiprazole may not only be a simply partial D(2) agonist but also a significant 5-HT(1A) agonist and 5-HT(2A) antagonist. These complex properties of antipsychotic aripiprazole may contribute to dopaminergic activation of the local circuitry in the prefrontal cortex of schizophrenic patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0079-6123(08)00910-2

Cites

84 of 84 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 84 references

Cited by

See all 147

Metadata

Authors
KUROKI, T., NAGAO, N., & NAKAHARA, T.
Affiliations
Hizen Psychiatric Center (JP)
Corresponding author
KUROKI, T
Venue
Progress in brain research
Publisher
Elsevier
Published
2008
Volume
172
Pages
199-212
ISSN
0079-6123 (ISSN-L)
OpenAlex
W1495797590
Cited by
146
References
85
Citations by year
2025: 8 · 2024: 7 · 2023: 3 · 2022: 5 · 2021: 2 · 2020: 7 · 2019: 10 · 2018: 9 · 2017: 9 · 2016: 12 · 2015: 5 · 2014: 13 · 2013: 8 · 2012: 15
FWCI
45.16
Type
book chapter
Language
en
Open access
closed
Locations
  • Progress in brain research (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
atypical antipsychotics, 5-HT2A receptor antagonism, dopamine D2 receptor antagonism, 5-HT1A receptor, aripiprazole, neurocognitive effects, schizophrenia, extrapyramidal symptoms, mechanism of action
MeSH terms
Animals, Dopamine, Humans, Receptors, Dopamine, Receptors, Serotonin, Schizophrenia, Serotonin, Serotonin Antagonists, Antipsychotic Agents, Prefrontal Cortex, Dopamine Antagonists, Protein Isoforms, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. https://app.cochat.ai/papers/10.1016/s0079-6123(08)00910-2
The paper
KUROKI, T., NAGAO, N., & NAKAHARA, T. (2008). Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Progress in brain research. https://doi.org/10.1016/s0079-6123(08)00910-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.